BeiGene Company Profile (NASDAQ:BGNE)

About BeiGene

BeiGene logoBeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton's tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BGNE
  • CUSIP:
Key Metrics:
  • Previous Close: $38.57
  • 50 Day Moving Average: $35.28
  • 200 Day Moving Average: $31.92
  • 52-Week Range: $32,933,000.00 - $24.53
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.47
  • P/E Growth: 0.00
  • Market Cap: $1.26B
  • Outstanding Shares: 32,933,000
Profitability:
  • Return on Equity: -79.29%
  • Return on Assets: -50.13%
Debt:
  • Debt-to-Equity Ratio: 0.10%
  • Current Ratio: 7.16%
  • Quick Ratio: 7.16%
Additional Links:
Companies Related to BeiGene:

Analyst Ratings

Consensus Ratings for BeiGene (NASDAQ:BGNE) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $40.00 (4.93% upside)

Analysts' Ratings History for BeiGene (NASDAQ:BGNE)
Show:
DateFirmActionRatingPrice TargetDetails
1/25/2017Maxim GroupSet Price TargetBuy$41.00View Rating Details
10/7/2016Cowen and CompanyReiterated RatingBuyView Rating Details
4/8/2016Morgan StanleyBoost Price Target$39.00 -> $42.00View Rating Details
2/29/2016Robert W. BairdInitiated CoverageOutperform$44.00View Rating Details
2/29/2016Goldman Sachs Group, Inc. (The)Initiated CoverageBuy$33.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for BeiGene (NASDAQ:BGNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/28/2017        
11/10/2016Q316($0.78)($1.08)$1.88 millionViewN/AView Earnings Details
8/10/2016Q2($0.68)($0.73)$2.08 million$0.40 millionViewN/AView Earnings Details
5/11/2016Q1($0.05)($0.97)$0.70 millionViewN/AView Earnings Details
3/30/2016Q4($1.06)($3.05)$1.74 million$4.68 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BeiGene (NASDAQ:BGNE)
Current Year EPS Consensus Estimate: $-3.64 EPS
Next Year EPS Consensus Estimate: $-3.64 EPS

Dividends

Dividend History for BeiGene (NASDAQ:BGNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BeiGene (NASDAQ:BGNE)
Institutional Ownership Percentage: 33.01%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/21/2017John OylerCEOSell64,963$40.55$2,634,249.65View SEC Filing  
11/23/2016Thomas MalleyDirectorBuy30,000$32.00$960,000.00View SEC Filing  
11/18/2016Bros. Advisors Lp BakerDirectorBuy1,760,495$32.00$56,335,840.00View SEC Filing  
9/28/2016Donald W GlazerDirectorSell41,463$30.66$1,271,255.58View SEC Filing  
9/27/2016Donald W GlazerDirectorSell47,149$29.61$1,396,081.89View SEC Filing  
9/23/2016Donald W GlazerDirectorSell36,443$31.02$1,130,461.86View SEC Filing  
9/21/2016Donald W GlazerDirectorSell67,252$31.42$2,113,057.84View SEC Filing  
2/8/2016Bros. Advisors Lp BakerDirectorBuy1,912,680$24.00$45,904,320.00View SEC Filing  
2/8/2016Howard LiangCFOBuy65,000$1.85$120,250.00View SEC Filing  
2/8/2016Ruirong YuanInsiderBuy130,000$1.85$240,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for BeiGene (NASDAQ:BGNE)
DateHeadline
marketexclusive.com logoInsider Trading Activity BeiGene, Ltd. (NASDAQ:BGNE) – CEO Sold 64,963 shares of Stock (NASDAQ:BGNE)
marketexclusive.com - February 22 at 3:58 PM
finance.yahoo.com logoBeiGene to Participate in the LEERINK Partners 6th Annual Global Healthcare Conference (NASDAQ:BGNE)
finance.yahoo.com - February 8 at 8:34 PM
News IconBeiGene Initiates Global Phase III Trial Of The BTK Inhibitor BGB-3111 In Waldenström's Macroglobulinemia (NASDAQ:BGNE)
www.clinicalleader.com - January 26 at 4:31 PM
insidermonkey.com logoBeigene Ltd (ADR) (BGNE): Here’s Our Take (NASDAQ:BGNE)
www.insidermonkey.com - January 26 at 4:30 PM
streetinsider.com logoBeiGene (BGNE) Initiates Global Phase III Trial of BTK Inhibitor BGB-3111 in WM (NASDAQ:BGNE)
www.streetinsider.com - January 26 at 1:23 AM
us.rd.yahoo.com logoBeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s Macroglobulinemia (NASDAQ:BGNE)
us.rd.yahoo.com - January 25 at 8:21 PM
4-traders.com logoBEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events (NASDAQ:BGNE)
www.4-traders.com - January 25 at 3:21 PM
News IconBeiGene Ltd BGNE Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:BGNE)
www.bioportfolio.com - January 7 at 1:26 AM
4-traders.com logoBeiGene : Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317 (NASDAQ:BGNE)
www.4-traders.com - December 31 at 3:51 PM
streetinsider.com logoBeiGene (BGNE) Doses First Patient in China Phase I Trial of BGB-A317 (NASDAQ:BGNE)
www.streetinsider.com - December 30 at 4:13 PM
publicnow.com logoBeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317 (NASDAQ:BGNE)
www.publicnow.com - December 30 at 4:12 PM
4-traders.com logoBeiGene : Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-290 (NASDAQ:BGNE)
www.4-traders.com - December 23 at 3:29 PM
streetinsider.com logoBeiGene (BGNE) Doses First Patient in China with BGB-290 in Phase I Trial (NASDAQ:BGNE)
www.streetinsider.com - December 22 at 1:32 AM
publicnow.com logoBeiGene Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-290 (NASDAQ:BGNE)
www.publicnow.com - December 21 at 8:31 PM
insidermonkey.com logoIs Federated National Holding Co (FNHC) A Good Stock To Buy? (NASDAQ:BGNE)
www.insidermonkey.com - December 14 at 3:16 PM
insidermonkey.com logoShould You Add Hawaiian Telcom HoldCo Inc (HCOM) to Your Portfolio? (NASDAQ:BGNE)
www.insidermonkey.com - December 14 at 3:16 PM
finance.yahoo.com logoBeiGene (BGNE): Strong Industry, Solid Earnings Estimate Revisions (NASDAQ:BGNE)
finance.yahoo.com - December 12 at 9:48 AM
insidermonkey.com logoShould You Buy Beigene Ltd (ADR) (BGNE)? (NASDAQ:BGNE)
www.insidermonkey.com - December 9 at 3:19 PM
finance.yahoo.com logoCancer Genetics, Inc. Is Selected by BeiGene, Ltd. to Collaborate on Clinical Trial Services & Advance Portfolio of Novel Oncology Therapeutics (NASDAQ:BGNE)
finance.yahoo.com - December 7 at 4:30 PM
streetinsider.com logoBeiGene (BGNE) Presents Updated BGB-3111 Phase 1 Data in CLL/SLL; Strong ORR and PFS Noted (NASDAQ:BGNE)
www.streetinsider.com - December 6 at 3:20 PM
finance.yahoo.com logoBeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia … (NASDAQ:BGNE)
finance.yahoo.com - December 6 at 3:20 PM
us.rd.yahoo.com logoBeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 2016 American Society of Hematology Annual Meeting (NASDAQ:BGNE)
us.rd.yahoo.com - December 6 at 5:10 AM
us.rd.yahoo.com logoBeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia at the 2016 American Society of Hematology Annual Meeting (NASDAQ:BGNE)
us.rd.yahoo.com - December 5 at 3:15 PM
us.rd.yahoo.com logo11:16 am BeiGene presents updated clinical data on BTK Inhibitor BGB-3111 in patients with chronic lymphocytic leukemia and small lymphocytic leukemia at the 2016 American Society of Hematology Annual Meeting (NASDAQ:BGNE)
us.rd.yahoo.com - December 5 at 3:15 PM
publicnow.com logoBeiGene Announces Closing of $200 Million Public Offering (NASDAQ:BGNE)
www.publicnow.com - November 23 at 9:52 PM
finance.yahoo.com logoBEIGENE, LTD. Financials (NASDAQ:BGNE)
finance.yahoo.com - November 18 at 3:49 PM
finance.yahoo.com logoBeiGene Announces Pricing of $200 Million Public Offering (NASDAQ:BGNE)
finance.yahoo.com - November 17 at 8:26 PM
finance.yahoo.com logoBeiGene Prices Secondary Offering (NASDAQ:BGNE)
finance.yahoo.com - November 17 at 1:27 PM
4-traders.com logoBEIGENE : LTD. (BGNE) Files An 8-K Other Events (NASDAQ:BGNE)
www.4-traders.com - November 16 at 9:00 PM
finance.yahoo.com logoBeiGene Announces Proposed Public Offering (NASDAQ:BGNE)
finance.yahoo.com - November 16 at 9:00 PM
prnewswire.com logoIPOs and Transactions: Nov 7 – 11 / plus 2017 SEC Filing Deadline calendar (NASDAQ:BGNE)
irblog.prnewswire.com - November 14 at 3:21 PM
biz.yahoo.com logoBEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:BGNE)
biz.yahoo.com - November 14 at 8:37 AM
streetinsider.com logoBeiGene (BGNE) Updates on BGB-A317 Phase 1; Seven Treatment-Related SAEs Noted (NASDAQ:BGNE)
www.streetinsider.com - November 12 at 12:15 PM
4-traders.com logoBeiGene : reports 3Q loss (NASDAQ:BGNE)
www.4-traders.com - November 11 at 12:04 PM
biz.yahoo.com logoBEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:BGNE)
biz.yahoo.com - November 10 at 1:17 PM
publicnow.com logoBeiGene Reports Third Quarter 2016 Financial Results (NASDAQ:BGNE)
www.publicnow.com - November 10 at 1:17 PM
finance.yahoo.com logoBeigene Files for Secondary Offering (NASDAQ:BGNE)
finance.yahoo.com - November 10 at 1:17 PM
finance.yahoo.com logoBeiGene Announces Oral Presentations on BTK Inhibitor BGB-3111 at the 2016 American Society of Hematology Annual Meeting (NASDAQ:BGNE)
finance.yahoo.com - November 3 at 1:14 PM
finance.yahoo.com logoBeiGene to Participate in 25th Annual Credit Suisse Healthcare Conference (NASDAQ:BGNE)
finance.yahoo.com - November 1 at 9:16 PM
4-traders.com logoBeiGene, Ltd. (NASDAQ:BGNE) Files An 8-K (NASDAQ:BGNE)
www.4-traders.com - October 12 at 8:15 AM
streetinsider.com logoBeiGene (BGNE) Offers Updated Data on BGB-3111 Phase 1; ORR at 92%, VGPR at 33% (NASDAQ:BGNE)
www.streetinsider.com - October 9 at 3:42 PM
finance.yahoo.com logoAbbVie, BeiGene Presents First Clinical Data for New Cancer Treatment (NASDAQ:BGNE)
finance.yahoo.com - October 8 at 8:37 AM
benzinga.com logoBeiGene Presents Updated Clinical Data on BTK... (NASDAQ:BGNE)
www.benzinga.com - October 7 at 3:48 PM
biz.yahoo.com logoBEIGENE, LTD. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:BGNE)
biz.yahoo.com - October 7 at 3:48 PM
publicnow.com logoBeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenstrom’s Macroglobulinemia at 9th International Workshop on Waldenstrom’s Macroglobulinemia (NASDAQ:BGNE)
www.publicnow.com - October 7 at 3:48 PM
biz.yahoo.com logoBeiGene Ltd Conference Call on BGB-3111 Data Presentation at IWWM-9 scheduled for 11:00 am ET today (NASDAQ:BGNE)
biz.yahoo.com - October 7 at 3:48 PM
thestreet.com logoProcter & Gamble and 6 Other Stocks Spiking on Big Volume (NASDAQ:BGNE)
www.thestreet.com - October 6 at 8:28 AM
finance.yahoo.com logo4:18 pm BeiGene announces that updated data from its Phase I study of BGB-3111 in patients with WM will be presented at the IWWM-9 on October 7 and updated BGB-A317 data at the SITC Annual Meeting on November 11-13 (NASDAQ:BGNE)
finance.yahoo.com - October 5 at 8:44 AM
publicnow.com logoBeiGene to Host Conference Call on BGB-3111 Data Presentation at IWWM-9 (NASDAQ:BGNE)
www.publicnow.com - October 5 at 8:44 AM
publicnow.com logoBeiGene Appoints Ross Pettit as Senior Vice President, Global Development Operations (NASDAQ:BGNE)
www.publicnow.com - October 4 at 8:37 AM

Social

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Where is BeiGene's stock going? Where will BeiGene's stock price be in 2017?

5 brokers have issued 1-year target prices for BeiGene's shares. Their forecasts range from $33.00 to $44.00. On average, they anticipate BeiGene's share price to reach $40.00 in the next twelve months.

When will BeiGene announce their earnings?

BeiGene is scheduled to release their next quarterly earnings announcement on Tuesday, March, 28th 2017.

What are analysts saying about BeiGene stock?

Here are some recent quotes from research analysts about BeiGene stock:

  • According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (1/17/2017)

  • Maxim Group analysts commented, "Today, AbbVie presented a five-year analysis and follow-up data of its BTK inhibitor Imbruvica (ibrutinib) for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) at the American Society of Hematology’s (ASH) Annual Meeting and Exposition. Conclusion. While BeiGene’s Phase I study data is still early compared to Imbruvica’s five-year follow-up analysis in a larger patient population, BGB-3111 showed a high response rate in relapsed/refractory CLL/SLL at a lower dose than Imbruvica at median follow-up of 7.5 months. Data so far supports BGB-3111’s demonstration of high potency and greater selectivity vs. Imbruvica, which could potentially be the best-in-class BTK inhibitor, pending additional data from clinical development." (12/5/2016)

  • Cowen and Company analysts commented, "BeiGene reported positive Phase I data in Waldenstrom’s Macroglobulinemia (WM) for." (10/7/2016)

Who owns BeiGene stock?

BeiGene's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (11.78%), Orbimed Advisors LLC (2.74%), Boxer Capital LLC (2.58%), Brown Advisory Inc. (1.39%), Temasek Holdings Private Ltd (1.15%) and Artal Group S.A. (0.91%). Company insiders that own BeiGene stock include Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, John Oyler, Ruirong Yuan and Thomas Malley.

Who bought BeiGene stock? Who is buying BeiGene stock?

BeiGene's stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, FMR LLC, Boxer Capital LLC, Artal Group S.A., Brown Advisory Inc., Guggenheim Capital LLC, State Street Corp and Baillie Gifford & Co.. Company insiders that have bought BeiGene stock in the last two years include Bros Advisors Lp Baker, Howard Liang, Ruirong Yuan and Thomas Malley.

How do I buy BeiGene stock?

Shares of BeiGene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BeiGene stock cost?

One share of BeiGene stock can currently be purchased for approximately $38.12.

BeiGene (NASDAQ:BGNE) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for BeiGene (NASDAQ:BGNE)

Earnings History Chart

Earnings by Quarter for BeiGene (NASDAQ:BGNE)

Dividend History Chart

Dividend Payments by Quarter for BeiGene (NASDAQ:BGNE)

Last Updated on 2/27/2017 by MarketBeat.com Staff